Minerva Neurosciences Inc. – Recovery of Investment Losses
The White Law Group is investigating potential securities claims involving broker-dealers who may have unsuitably recommended Minerva Neurosciences Inc. to investors.
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, reportedly engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases.
The company reportedly filed a form D to raise capital from investors in 2015. The total offering amount sold was purportedly $30,999,997.
Minerva Biosciences’ shares have declined more than -60% in the past 12 months, according to MarketWatch. According to analysts, the decline is due to disappointing results from a phase 3 trial of its schizophrenia treatment.